Home > Services  > Monash Infectious Diseases  > Research  > Staphylococcal Infection > VANESSA (efficacy of vancomycin)

VANESSA (efficacy of vancomycin)

VANESSA (VANcomycin Efficacy in Staphylococcal Sepsis in Australasia): a prospective, multi-centre, observational cohort study of outcomes in Staphylococcus aureus bacteraemia.

Monash Infectious Diseases is participating in this study, which is evaluating outcomes of vancomycin treatment for methicillin-susceptible and methicillin-resistant Staphylococus aureus bacteraemia. The study is one of the first projects approved by the Australasian Society for Infectious Diseases (ASID) Clinical Research Network.

Study Coordinator: Dr Natasha Holmes

Participating Sites

  • Alfred Hospital
  • Auckland District Health
  • Austin Health
  • Geelong Hospital
  • Ipswich Hospital
  • Liverpool Hospital
  • Monash Infectious Diseases
  • Northern Hospital
  • Princess Alexandra Hospital
  • Royal Perth Hospital

Introduction
The  preliminary result from the vancomycin sub-study of ANZCOSS suggests that factors other than poor vancomycin efficacy per se are responsible for the inferior outcome in these patiients.

Objective
To assess outcomes from S. aureus bacteraemia in Australasia and determine possible predictors of mortality using patient, organism and pharmacological factors.